Second consecutive quarter of net income of $0.4 million Revenue increased to $11.4 million, led by growth from USUDisciplined cost controls deliver operating income of $0.7 millionPositive Adjusted EBITDA of $1.9 million as compared to $0.4 millionThird consecutive quarter of positive operating cash flow of $0.4 million PHOENIX, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Aspen Group, Inc. (OTCQB: ASPU) (“AGI” or the “Company”), an education technology holding company, today announced financial results for its first ...

Platform enhancements build on the most competitive advisory offering in the industrySAN DIEGO, Oct. 31, 2025 (GLOBE NEWSWIRE) -- LPL Financial LLC, a leading wealth management firm, today announced a reduction in fees and a simplified pricing structure across its advisory platforms, delivering meaningful savings in high-demand programs and helping advisors expand access to high-value investment solutions. Effective July 1, 2026, fees will be lowered for advisors across LPL’s Strategic Asset Management (SAM ...

Alps ordinary shares to list on the Nasdaq under the symbol “ALPS” on October 31, 2025KUALA LUMPUR, Malaysia and NEWARK, Del., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Alps Group Inc (the “Company” or “Alps Group”), the parent company of Alps Life Sciences Inc. (“Alps Holdco”), a fully integrated biotechnology research and healthcare platform specializing in predictive, preventive, and precision medicine, and Globalink Investment Inc., a Delaware corporation and a special purpose acquisition company (“Globalink”), ...

Core Insights - Evaxion A/S is set to provide a business update and report its Q3 2025 financial results on October 31, 2025, before the Nasdaq CM opens [1] - The company's Executive Management will host a conference call and webcast on the same day at 14:30 CET/08:30 EST, which is open to the public [2] - Evaxion specializes in AI-Immunology™ powered vaccines, focusing on developing novel immunotherapies for cancer, bacterial diseases, and viral infections [4] Company Overview - Evaxion A/S is a pioneering TechBio company utilizing its AI platform, AI-Immunology™, to decode the human immune system [4] - The company has developed a clinical-stage oncology pipeline of personalized vaccines and a preclinical pipeline targeting bacterial and viral diseases with high unmet medical needs [4] - Evaxion aims to transform patients' lives by providing innovative and targeted treatment options [4]

IRVING, Texas, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Sow Good Inc. (Nasdaq: SOWG) (“Sow Good” or “the Company”), a trailblazer in the freeze dried candy and treat industry, will hold a conference call on Friday, November 14, 2025, at 10:00 a.m. Eastern time to discuss its results for the third quarter ended September 30, 2025. The Company will provide its financial results in a press release prior to the conference call. Date: Friday, November 14, 2025Time: 10:00 a.m. Eastern timeRegistration Link: https://regi ...

ANNISTON, Ala., Oct. 31, 2025 (GLOBE NEWSWIRE) -- (TSX: NFI, OTC: NFYEF, TSX: NFI.DB) NFI Group Inc. (NFI) a leader in propulsion-agnostic bus and coach mobility solutions, subsidiary New Flyer of America Inc. (New Flyer), is proud to announce that it has been named the Employer of the Year – Large Business by the Alabama Governor’s Committee on Employment of People with Disabilities (GCEPD). The award recognizes New Flyer’s strong commitment to accessibility and support for employees with disabilities in A ...

TAMPA, Fla., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ: UPXI) (the “Company” or “Upexi”), a leading Solana-focused digital asset treasury company and consumer brands owner, today announced that management will participate in the following November 2025 investor conferences. Details for each conference can be found below. The link to webcasted presentations can be found on our Investor Relations website here: https://ir.upexi.com/news-events/ir-calendar. New Orleans Investment ConferenceDate: Nov ...

Core Insights - Getty Images and Perplexity have entered into a global multi-year licensing agreement allowing Perplexity to display Getty Images' visuals in its AI-powered search tools, enhancing user experience and image attribution [3][4][5] Company Overview - Getty Images is a leading global visual content creator and marketplace, serving customers worldwide through its brands including Getty Images, iStock, and Unsplash, and collaborating with nearly 600,000 content creators [7][8] - Perplexity, founded in 2022, is an AI-powered answer engine that provides accurate answers from credible sources, handling over 150 million questions globally each week [10] Agreement Details - The agreement integrates Getty Images' API technology into Perplexity's content creation workflows, providing access to high-quality imagery and improving how images are displayed, including proper attribution [4][5] - Both companies emphasize the importance of content attribution and accuracy in the age of AI, aiming to enhance user engagement and reliability of information [5][6]

Core Insights - American Battery Technology Company (ABTC) participated in the IEA Energy Innovation Forum 2025, highlighting its role in advancing sustainable energy solutions and critical battery materials [1][5] - CEO Ryan Melsert was invited to give the opening talk on securing critical battery mineral supplies, emphasizing the importance of innovation in energy technology [2][3] Company Overview - ABTC is recognized as a leader in clean energy solutions, focusing on battery recycling and sustainable mining of lithium, essential for the transition to renewable energy [4] - The company is committed to a circular supply chain for battery metals, aiming to meet the growing demand from electric vehicles, stationary storage, and consumer electronics [6] Industry Context - The IEA Energy Innovation Forum brought together 200 international experts to discuss energy technology innovation, with outcomes intended to inform the G7 Energy and Environment Ministers' Meeting [2] - Key topics discussed included artificial intelligence for energy technology, carbon dioxide removal, and battery mineral resilience, underscoring the need for international cooperation in the clean energy transition [3]

Core Insights - Clearmind Medicine Inc. has announced a U.S. patent application for its non-hallucinogenic compound MEAI, aimed at treating cocaine addiction, enhancing its intellectual property portfolio [1][2][4] - Cocaine use disorder is a significant global health issue with no FDA-approved treatments, presenting a market opportunity projected to grow from $1.36 billion in 2025 to $2.03 billion by 2032 [2] - MEAI is designed to modulate serotonin and dopamine pathways, potentially offering a safer alternative to existing behavioral interventions for addiction [3][4] Company Overview - Clearmind is a clinical-stage biotech company focused on developing novel neuroplastogen-derived therapeutics for under-treated health problems, including addiction [1][4] - The company currently holds nineteen patent families with 31 granted patents and plans to pursue additional patents to strengthen its intellectual property [5] Market Context - The global market for cocaine addiction treatment is experiencing urgent demand for new solutions, highlighting the potential impact of Clearmind's developments in this area [2][3]